Type 1 DiabetesNCT00793741
Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness
An observational study of Type 1 Diabetes and Hypoglycemia Unawareness, run by University of Minnesota at 1 site in United States.
Trial summary
The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes, Hypoglycemia Unawareness
- What is being tested?
- somatostatin
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- Dec 2007to Mar 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Endocrinology clinic, community
Who may be able to join
- Age 18-65
- Must be able to provide informed consent
- Type 1 diabetes >5 years duration
- Healthy controls
Who cannot join
- Over 300 pounds
- Claustrophobic
- History of ischemic heart disease, arrhythmia or seizure disorder
- Pregnant
- On medications known to alter blood flow or carbohydrate metabolism
- Have internally located pieces of metal
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Minnesota
Minneapolis, Minnesota, 55455
About this study
The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects.
Read the detailed description
Individuals with type 1 diabetes and hypoglycemia unawareness who become active islet transplant candidates and matched controls will be recruited for participation in this study. Subjects will undergo a hyperglycemic clamp with somatostatin before and 6 months after islet transplantation. During the clamp study, their brain glucose concentrations will be measured by proton magnetic resonance spectroscopy. Following these measurements, subjects will undergo a hypoglycemic clamp study to assess their counterregulatory response.
On the morning of the study subjects will report to the Clinical Research Center in the CMRR and be asked to do the following:
- All subjects will be asked not to eat anything after midnight on the day before the magnet study at the Magnet Center. A small plastic catheter will be placed in a vein in each arm for infusion of hormones. A third plastic catheter will be placed in a foot vein for measuring blood glucose levels. The foot and distal leg will be placed in a heated blanket for the duration of the study to speed up the flow of blood through the vein and for easy withdrawing of blood. During the study subjects will receive carefully calculated doses of insulin, glucose, potassium phosphate, and somatostatin. These substances will be contained in syringes or bags and pumped through intravenous catheters placed in the arms. Insulin and somatostatin are hormones that are made naturally by the body. Initially we will keep blood sugar at the normal level. The blood glucose will then be raised by infusing glucose at a calculated rate. We will maintain the high blood sugar concentration for 45 to 120 minutes. This causes no symptoms other than a necessity f to pass urine more frequently than normal. The blood glucose infusion will then be dropped to allow blood glucose to drop in small steps to the normal glucose concentration. We will draw at most 15 oz. of blood during this part of the study.
- All subjects will be asked to participate in a second experiment after the magnet study. Subjects may chose to perform this part of the study at Yale University. If subjects choose to stay at the University Of Minnesota, they will be participating in the second experiment either the same day or the day after the first experiment. If done the same day, the arm catheters will be left in place for infusion of insulin, potassium phosphate, and glucose. A third catheter may be placed in the hand for venous blood sampling. This hand will be placed in a warming box to ensure adequate blood flow and accurate laboratory results. Blood will be drawn every 5 minutes for measurement of glucose and other hormones. The total amount of blood drawn will be about 10 tablespoons. Insulin will be infused to lower blood sugar level to a level below the normal range. It will be maintained at this low level for thirty minutes after which time the insulin infusion will be discontinued and the blood sugar level allowed to normalize. Subjects will then be given a meal.
- Subjects with type 1 diabetes will be asked to spend the night before each study at the General Clinical Research Center so that blood glucose values can be maintained between 80-110 mg/dl. They will be asked to hold insulin doses in the evening before and on the morning of the study and insulin will be provided via an intravenous infusion. For those subjects with diabetes who chose to undergo all testing at the University of Minnesota, they will be followed as inpatients in the GCRC during one to two days of testing.
- Following islet transplant subjects will be asked to undergo the magnet study described under point #1 above and the hypoglycemia study described under point #3 above at approximately 3-9 months after the procedure.
- Conditions
- Type 1 Diabetes, Hypoglycemia Unawareness
- Being tested
- somatostatin
- Keywords
- Type 1 diabetes, Hypoglycemia unawareness, Islet transplant
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
somatostatinDrug
Somatostatin may be used to suppress endogenous insulin secretion
| Study group | Role | What they receive |
|---|---|---|
| 1 | Type 1 Diabetes Hypoglycemia unawareness Islet transplant candidate Receives: Drug: somatostatin | |
| 2 | Healthy control subjects Receives: Drug: somatostatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Brain glucose concentration as measured by NMR spectroscopy
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2008 (estimated)
- Study startDec 2007
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 DiabetesStudies of the same condition, open and under way.
- More trials run by University of MinnesotaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Minnesota
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Elizabeth R Seaquist, MD, Principal investigator, University of Minnesota
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00793741
- Sponsor's protocol ID
- 9711M00055
- Status last verified
- Jan 2018
- First submitted
- 18 Nov 2008
- Last updated
- 18 Jan 2018
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness
- ClinicalTrials.gov ID
- NCT00793741
- Acronym / sponsor ID
- 9711M00055
- Conditions
- Type 1 Diabetes, Hypoglycemia Unawareness
- Keywords
- Type 1 diabetes, Hypoglycemia unawareness, Islet transplant
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- University of MinnesotaUniversity, hospital or other
- Study start
- Dec 2007 (actual)
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 19 Nov 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether islet transplantation alters brain glucose concentrations in patients with type 1 diabetes, recurrent hypoglycemia, and hypoglycemia unawareness when compared to that measured prior to transplant in the same subjects.
Detailed description
Individuals with type 1 diabetes and hypoglycemia unawareness who become active islet transplant candidates and matched controls will be recruited for participation in this study. Subjects will undergo a hyperglycemic clamp with somatostatin before and 6 months after islet transplantation. During the clamp study, their brain glucose concentrations will be measured by proton magnetic resonance spectroscopy. Following these measurements, subjects will undergo a hypoglycemic clamp study to assess their counterregulatory response.
On the morning of the study subjects will report to the Clinical Research Center in the CMRR and be asked to do the following:
- All subjects will be asked not to eat anything after midnight on the day before the magnet study at the Magnet Center. A small plastic catheter will be placed in a vein in each arm for infusion of hormones. A third plastic catheter will be placed in a foot vein for measuring blood glucose levels. The foot and distal leg will be placed in a heated blanket for the duration of the study to speed up the flow of blood through the vein and for easy withdrawing of blood. During the study subjects will receive carefully calculated doses of insulin, glucose, potassium phosphate, and somatostatin. These substances will be contained in syringes or bags and pumped through intravenous catheters placed in the arms. Insulin and somatostatin are hormones that are made naturally by the body. Initially we will keep blood sugar at the normal level. The blood glucose will then be raised by infusing glucose at a calculated rate. We will maintain the high blood sugar concentration for 45 to 120 minutes. This causes no symptoms other than a necessity f to pass urine more frequently than normal. The blood glucose infusion will then be dropped to allow blood glucose to drop in small steps to the normal glucose concentration. We will draw at most 15 oz. of blood during this part of the study.
- All subjects will be asked to participate in a second experiment after the magnet study. Subjects may chose to perform this part of the study at Yale University. If subjects choose to stay at the University Of Minnesota, they will be participating in the second experiment either the same day or the day after the first experiment. If done the same day, the arm catheters will be left in place for infusion of insulin, potassium phosphate, and glucose. A third catheter may be placed in the hand for venous blood sampling. This hand will be placed in a warming box to ensure adequate blood flow and accurate laboratory results. Blood will be drawn every 5 minutes for measurement of glucose and other hormones. The total amount of blood drawn will be about 10 tablespoons. Insulin will be infused to lower blood sugar level to a level below the normal range. It will be maintained at this low level for thirty minutes after which time the insulin infusion will be discontinued and the blood sugar level allowed to normalize. Subjects will then be given a meal.
- Subjects with type 1 diabetes will be asked to spend the night before each study at the General Clinical Research Center so that blood glucose values can be maintained between 80-110 mg/dl. They will be asked to hold insulin doses in the evening before and on the morning of the study and insulin will be provided via an intravenous infusion. For those subjects with diabetes who chose to undergo all testing at the University of Minnesota, they will be followed as inpatients in the GCRC during one to two days of testing.
- Following islet transplant subjects will be asked to undergo the magnet study described under point #1 above and the hypoglycemia study described under point #3 above at approximately 3-9 months after the procedure.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | – | Drug: somatostatinType 1 Diabetes Hypoglycemia unawareness Islet transplant candidate |
| 2 | – | Drug: somatostatinHealthy control subjects |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Endocrinology clinic, community
Key inclusion criteria (4 listed)
- Age 18-65
- Must be able to provide informed consent
- Type 1 diabetes >5 years duration
- Healthy controls
Key exclusion criteria (6 listed)
- Over 300 pounds
- Claustrophobic
- History of ischemic heart disease, arrhythmia or seizure disorder
- Pregnant
- On medications known to alter blood flow or carbohydrate metabolism
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| somatostatinSomatostatin may be used to suppress endogenous insulin secretion | Drug | 1, 2 |
Primary outcome
Brain glucose concentration as measured by NMR spectroscopy
Time frame: 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2018.
Related trials for Type 1 Diabetes
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elizabeth R Seaquist, MD principal investigator
University of Minnesota
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 1 Diabetes and Hypoglycemia Unawareness, run by University of Minnesota at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Brain glucose concentration as measured by NMR spectroscopy (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2018.